These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38216922)

  • 1. Changes in dementia treatment patterns associated with changes in the National Policy in South Korea among patients with newly diagnosed Alzheimer's disease between 2011 and 2017: results from the multicenter, retrospective CAPTAIN study.
    Kim YJ; So KY; Lee HM; Hahn C; Song SH; Lee YS; Kim SW; Park HC; Ryu J; Lee JS; Kang MJ; Kim J; Lee Y; Lee JH
    BMC Public Health; 2024 Jan; 24(1):168. PubMed ID: 38216922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.
    Mucha L; Shaohung S; Cuffel B; McRae T; Mark TL; Del Valle M
    J Manag Care Pharm; 2008 Jun; 14(5):451-61. PubMed ID: 18597574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Start of Anti-Dementia Medication Delays Transition to 24-Hour Care in Alzheimer's Disease Patients: A Finnish Nationwide Cohort Study.
    Halminen O; Vesikansa A; Mehtälä J; Hörhammer I; Mikkola T; Virta LJ; Ylisaukko-Oja T; Linna M
    J Alzheimers Dis; 2021; 81(3):1103-1115. PubMed ID: 33843673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Dementia Drug Persistence Following Donepezil Initiation Among Alzheimer's Disease Patients in Japan: LIFE Study.
    Fukuda H; Maeda M; Murata F; Murata Y
    J Alzheimers Dis; 2022; 90(3):1177-1186. PubMed ID: 36213993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
    Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
    Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donepezil for dementia due to Alzheimer's disease.
    Birks JS; Harvey RJ
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD001190. PubMed ID: 29923184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.
    Parsons C; Lim WY; Loy C; McGuinness B; Passmore P; Ward SA; Hughes C
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD009081. PubMed ID: 35608903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease state changes and safety of long-term donepezil hydrochloride administration in patients with Alzheimer's disease: Japan-Great Outcome of Long-term trial with Donepezil (J-GOLD).
    Arai H; Hashimoto N; Sumitomo K; Takase T; Ishii M
    Psychogeriatrics; 2018 Sep; 18(5):402-411. PubMed ID: 29993162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses.
    Howard R; McShane R; Lindesay J; Ritchie C; Baldwin A; Barber R; Burns A; Dening T; Findlay D; Holmes C; Jones R; Jones R; McKeith I; Macharouthu A; O'Brien J; Sheehan B; Juszczak E; Katona C; Hills R; Knapp M; Ballard C; Brown RG; Banerjee S; Adams J; Johnson T; Bentham P; Phillips PP
    Lancet Neurol; 2015 Dec; 14(12):1171-81. PubMed ID: 26515660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.
    Farlow MR; Salloway S; Tariot PN; Yardley J; Moline ML; Wang Q; Brand-Schieber E; Zou H; Hsu T; Satlin A
    Clin Ther; 2010 Jul; 32(7):1234-51. PubMed ID: 20678673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of treatment pattern of anti-dementia medications in newly diagnosed Alzheimer's dementia using OMOP CDM.
    Byun J; Lee DY; Jeong CW; Kim Y; Rhee HY; Moon KW; Heo J; Hong Y; Kim WJ; Nam SJ; Choi HS; Park JI; Chun IK; Bak SH; Lee K; Byeon GH; Kim KL; Kim JA; Park YJ; Kim JH; Lee EJ; Lee SA; Kwon SO; Park SW; Kasani PH; Kim JK; Kim Y; Kim S; Jang JW
    Sci Rep; 2022 Mar; 12(1):4451. PubMed ID: 35292697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study.
    Samuel W; Caligiuri M; Galasko D; Lacro J; Marini M; McClure FS; Warren K; Jeste DV
    Int J Geriatr Psychiatry; 2000 Sep; 15(9):794-802. PubMed ID: 10984725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal Neuropsychological Outcome in Taiwanese Alzheimer's Disease Patients Treated with Medication.
    Yang YH; Wu MN; Chou PS; Su HC; Lin SH; Sung PS
    Curr Alzheimer Res; 2018 Mar; 15(5):474-481. PubMed ID: 29032750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of treated patients with Alzheimer's disease: current trends and COVID-19 impact.
    Olazarán J; Carnero-Pardo C; Fortea J; Sánchez-Juan P; García-Ribas G; Viñuela F; Martínez-Lage P; Boada M
    Alzheimers Res Ther; 2023 Aug; 15(1):130. PubMed ID: 37537656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholinesterase inhibitors for Alzheimer's disease.
    Birks J
    Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD005593. PubMed ID: 16437532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world effectiveness, its predictors and onset of action of cholinesterase inhibitors and memantine in dementia: retrospective health record study.
    Vaci N; Koychev I; Kim CH; Kormilitzin A; Liu Q; Lucas C; Dehghan A; Nenadic G; Nevado-Holgado A
    Br J Psychiatry; 2021 May; 218(5):261-267. PubMed ID: 32713359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada.
    O'Brien BJ; Goeree R; Hux M; Iskedjian M; Blackhouse G; Gagnon M; Gauthier S
    J Am Geriatr Soc; 1999 May; 47(5):570-8. PubMed ID: 10323651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer's Disease: the MEMAGE study.
    Gareri P; Putignano D; Castagna A; Cotroneo AM; De Palo G; Fabbo A; Forgione L; Giacummo A; Lacava R; Marino S; Simone M; Zurlo A; Putignano S
    J Alzheimers Dis; 2014; 41(2):633-40. PubMed ID: 24643135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.